Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study

CONCLUSIONS: This study provides first-in-human evidence that P2Y12 inhibitor monotherapy directly following PCI for NSTE-ACS is feasible, without any overt safety concerns, and highlights the need for randomised controlled trials comparing direct P2Y12 inhibitor monotherapy with the current standard of care.PMID:36734020 | DOI:10.4244/EIJ-D-22-00886

Source: EuroIntervention - February 3, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Niels M R van der Sangen Bimmer E P M Claessen I Tarik K üçük Alexander W den Hartog Jan Baan Marcel A M Beijk Ronak Delewi Tim P van de Hoef Paul Knaapen Jorrit S Lemkes Koen M Marques Alexander Nap Niels J W Verouden M Marije Vis Robbert J de Winter Source Type: research